![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Three Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) With Chronic Hepatitis B (Study 103)
|
|
|
Reported by Jules Levin
60th Annual Meeting of the American Association
for the Study of Liver Diseases
October 30 - November 3, 2009
Boston, Massachusetts, USA
E J Heathcote1, E Gane2, R deMan3, S S Lee4, R Flisiak5, M Manns6, K Tchernev7, O Kurdas8, M Shiffman9, P Marcellin10, J Sorbel11, J Anderson11, E Mondou11, and F Rousseau11
1University of Toronto, Ontario Canada; 2Middlemore Hospital, Auckland New Zealand; 3Erasmus MC, University Medical Center Rotterdam, The Netherlands; 4University of Calgary, Calgary AB Canada; 5Medical University of
Bialystok, Bialystok Poland; 6Medical School of Hannover (MHH), Hannover, Germany; 7Medical University, Sofi a Bulgaria; 8Haydarpapa Nu
![image002.gif](../images/110609/110609-10/image002.gif)
BACKGROUND
Tenofovir DF (TDF) was approved for HIV-1 in 2001 and chronic hepatitis B (CHB) in 2008: ∼ 2.4 million patient-years of experience
Week 48 Phase 3 data showed TDF superior to adefovir dipivoxil (ADV): 76% of HBeAg-positive TDF-treated patients (versus 13% ADV-treated patients) had HBV DNA <400 copies/mL
TDF treatment in HBeAg-positive patients beyond Week 48 showed:
- Both stable and viremic patients on ADV can effectively switch to TDF and achieve or maintain viral suppression (HBV DNA < 400 copies/mL), normal ALT and increasing HBeAg and HBsAg loss at Week 96
- TDF patients treated for 96 weeks maintained HBV DNA < 400 copies/mL, normal ALT levels and experienced increasing HBeAg and HBsAg loss
OBJECTIVE
Evaluate the safety and effi cacy of up to 3 years of TDF therapy
![image004.gif](../images/110609/110609-10/image004.gif)
![image006.gif](../images/110609/110609-10/image006.gif)
![image008.gif](../images/110609/110609-10/image008.gif)
*Patients had the option to add FTC 200 mg at the discretion of the investigator if confirmedHBV DNA ≥400 copies/ml at week 72 or beyond
![image010.gif](../images/110609/110609-10/image010.gif)
![image012.gif](../images/110609/110609-10/image012.gif)
![image014.gif](../images/110609/110609-10/image014.gif)
![image016.gif](../images/110609/110609-10/image016.gif)
![image018.gif](../images/110609/110609-10/image018.gif)
![image020.gif](../images/110609/110609-10/image020.gif)
![image022.gif](../images/110609/110609-10/image022.gif)
![image024.gif](../images/110609/110609-10/image024.gif)
![image026.gif](../images/110609/110609-10/image026.gif)
![image028.gif](../images/110609/110609-10/image028.gif)
![image030.gif](../images/110609/110609-10/image030.gif)
![image032.gif](../images/110609/110609-10/image032.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|